Case Report: Reopening the anabolic window — romosozumab added to ongoing denosumab for severe osteoporosis in two kidney transplant recipients - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Case Study: Reactivating the Anabolic Window — The Use of Romosozumab Alongside Denosumab in Two Female Patients with Severe Osteoporosis Post-Kidney Transplant

  • By

  • Simona Barbuto

  • Paolo Mastromauro

  • Guido Zavatta

  • Daniele Vetrano

  • Anna Mistretta

  • Nicolò Bisceglia

  • Giorgia Comai

  • Uberto Pagotto

  • Gaetano La Manna

  • Giuseppe Cianciolo

  • September 4, 2026

Share

Clinical Scorecard: Case Study: Reactivating the Anabolic Window — The Use of Romosozumab Alongside Denosumab in Two Female Patients with Severe Osteoporosis Post-Kidney Transplant

At a Glance

CategoryDetail
ConditionSevere Osteoporosis Post-Kidney Transplant
Key MechanismsInhibition of sclerostin, anabolic and antiresorptive effects
Target PopulationKidney transplant recipients with osteoporosis
Care SettingClinical management of osteoporosis in kidney transplant recipients

Key Highlights

  • Romosozumab added to denosumab increased lumbar spine BMD by 5.9% and 11.2% in two patients.
  • No clinically significant hypocalcemia occurred during treatment.
  • Both patients showed early increases in bone-formation markers P1NP and BAP.

Guideline-Based Recommendations

Diagnosis

  • Assessment of bone mineral density (BMD) in kidney transplant recipients.

Management

  • Consideration of combination therapy with romosozumab and denosumab for severe osteoporosis.

Monitoring & Follow-up

  • Regular monitoring of serum calcium, parathyroid hormone, and vitamin D levels.

Risks

  • Increased fracture risk in kidney transplant recipients due to osteoporosis.

Patient & Prescribing Data

Female kidney transplant recipients with severe osteoporosis.

Combination therapy with romosozumab and denosumab may enhance bone density without compromising mineral metabolism.

Clinical Best Practices

  • Individualize antiosteoporotic therapy based on bone phenotype and turnover state.
  • Correct vitamin D deficiency and insufficiency in kidney transplant recipients.

Related Resources & Content

Original Source(s)

Related Content